
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SYT CRISPR Activation Plasmid (h) | sc-401575-ACT | 20 µg | $397.00 |
SS18, also known as SYT, encodes a nuclear transcriptional co-regulator that associates with SWI/SNF (BAF) chromatin remodeling complexes to influence enhancer and promoter accessibility. Through these interactions, SS18 helps coordinate RNA polymerase II–dependent transcriptional programs linked to cell identity, differentiation, and proliferation. SS18 is disease-relevant because recurrent rearrangements involving SS18 can rewire chromatin regulation and aberrantly activate lineage-inappropriate gene expression, making it a key node for studying oncogenic transcriptional dependencies. Its function is commonly investigated in the context of chromatin remodeling, epigenetic state control, and transcription factor network dynamics.
SYT CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SS18 expression without altering the underlying DNA sequence.
SYT CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SS18 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SS18 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous SYT expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SS18 locus and enabling the study of SYT-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of SYT pathway restoration in tumor cells with silenced or reduced SS18 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.